tbuckley/cabot-search huggingface dataset:
Abstract P258: Physical Activity Attenuates the Impact of Obesity on Cardiometabolic Risk: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Paul A McAuley, Haiying Chen, Duck-chul Lee, Enrique G Artero, David A Bluemke, Greg L Burke
Journal: Circulation (2012)

Background: The impact of higher physical activity on the relationship between adiposity and cardiometabolic risk is not completely understood. Methods: The cross-sectional association between body mass index (BMI) and cardiometabolic risk stratified by intentional physical activity was examined in 6814 Multi-Ethnic Study of Atherosclerosis participants, during 2000-2002. Self-reported physical activity in the lowest quartile (0-105 MET-minutes/wk) was categorized as inactive with the upper three quartiles (123-37,260 MET-minutes/wk) categorized as active. The association of BMI categories of normal-weight, overweight and obese stratified by physical activity status (inactive or active) with cardiometabolic risk factors (low HDL-cholesterol [&lt;50 mg/dL], high triglycerides [TG] [≥200 mg/dl], hypertension [HTN] [BP ≥140/90 or current treatment], insulin resistance [highest quartile of homeostasis model assessment of insulin resistance index (HOMA-IR)], and impaired fasting glucose [IFG] [≥100 mg/dl]/diabetes mellitus [DM]) were assessed using logistic regression analysis, after adjusting for age, gender, race/ethnicity, and current smoking. Results: As expected, overweight and obese participants had a more abnormal risk profile. Among obese participants, those with increased physical activity had reduced odds of insulin resistance (47% lower; p&lt;0.001) and IFG/DM (23% lower; p=0.04). Increased physical activity had a beneficial, but more modest effect on other traditional CVD risk factors ( Table ). Conclusion: A beneficial impact of physical activity on cardiometabolic risk was observed that partially attenuated the abnormal impact of obesity. Odds ratio (95% CI) for cardiometabolic abnormality by BMI-PA category Low-HDL High-TG HTN HOMA-IR IFG/DM Normal Active 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) Normal Inactive 1.3 (1.0-1.7) 1.4 (0.9-2.1) 1.1 (0.8-1.4) 1.1 (0.7-1.7) 1.0 (0.7-1.4) Overweight Active 1.9 (1.6-2.2) 2.1 (1.6-2.6) 1.5 (1.3-1.8) 3.2 (2.5-4.2) 2.1 (1.7-2.5) Overweight Inactive 2.5 (2.0-3.1) 2.0 (1.5-2.8) 1.5 (1.2-1.9) 3.8 (2.8-5.2) 2.1 (1.6-2.7) Obese Active 2.9 (2.4-3.7) 2.5 (1.9-3.4) 2.2 (1.8-2.7) 7.6 (5.6-10.2) 3.4 (2.7-4.4) Obese Inactive 3.1 (2.4-4.1) 2.7 (1.9-3.8) 2.5 (2.0-3.3) 14.3 (10.3-19.7) 4.4 (3.4-5.9)
Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.
Authors: R. Dhanasekaran, E. B. McIntosh, J. S. Kauh, D. A. Kooby, B. F. El-Rayes, H. S. Kim
Journal: Journal of Clinical Oncology (2010)

e14559 Background: Locoregional therapy (LRT) has long been used as palliative care for patients with unresectable hepatocellular carcinoma (HCC). Current study explores long-term survival after LRT in patients with unresectable hepatocellular carcinoma over a period of two decades. Methods: Consecutive patients who underwent LRT for unresectable hepatocellular carcinoma between 1990 and 2008 were included in the study. Clinical, laboratory and procedural data was collected for all patients by retrospective review. Patients were chronologically divided into 2 groups based on the year of first LRT (group 1 1990-99; group 2 2000-08). Chi square test was used to compare categorical variables and student t test to compare continuous variables. Kaplan Meier method was used for survival analysis. Survival curves were compared using the log-rank test. Results: 309 patients (mean age 60.5 years SD 11.6) had received LRT over the study period and were included in the study. Demongraphics were as follows- mean age of the study group was 60.5 yrs (SD 11.6); 73% (224/309) were male; and 71% were Caucasian. Tumor stagings included Okuda stages I, II and II of 44%, 45% and 10% and Child class A, B and C of 48%, 39% and 12%. The mean MELD score was 11.8 (SD 4.7). 22% (67/309) patients in group 1 and 78% (242/309) in group 2 -were statistically similar for age, sex, race, Child Pugh class, Okuda stage, MELD score and cumulative tumor size (p > 0.05). The median long-term survival in group 1 was 311 days (95% CI 212-409) and in group 2 it was 513 days (382-643) (p = 0.001). The survival rates at 6 months, 1 year and 3 years in group 1 were 72%, 41% and 16%, and those for group 2 were 78%, 63% and 30% (p = 0.001). Conclusions: There has been a significant improvement of long-term survival in the current decade for patients with unresectable HCC who undergo locoregional therapy, compared to the previous decade. No significant financial relationships to disclose.
The differences in rate and duration of complete remission between HER2-positive and HER2-negative inflammatory breast carcinoma
Authors: D. Kolarevic, Z. Tomasevic, N. Andjelic Dekic, S. Milosevic, S. Jelic
Journal: Journal of Clinical Oncology (2009)

1106 Background: Inflammatory breast carcinoma (IBC) is rare but aggressive form of breast cancer. Up to 38% of IBC are HER-2+. According to literature, complete remission (CR) can be achived in more than 50% of patients with combinatination of chemotherapy and trastuzumab. However, trastuzumab is still not available in all countries. The aim of this study was to evaluate the rate and duration of CR to induction chemotherapy alone, without trastuzumab, in HER-2+ and HER-2- IBC pts and compare our results to literature data. Methods: The data were analized for 3,452 breast carcinoma patients registered at the Institute for Oncology and Radiology of Serbia (IORS) during one year. Among them, 281 pts had IBC, defined as pathologically confirmed skin lymphangiosis or BC with classical clinical signs of cancer mastitis. Responses have been evaluated clinically and by mammography after every 3–4 cycles of chemotherapy. CR was estimated as a complete disappearance of previously palpable breast tumour; no clinical and mammography signs of cancer mastitis; no enlarged regional lymph nodes and disappearance of all metastatic sites in stage IV. HER-2 status (IHC, Dako) was assessed in 88 patients (70.9%) and 25/88 (28.4%) were HER-2 3+. Results: We investigated 124 IBC pts with complete medical records. The overall incidence of IBC was 8.1%. Median age at diagnosis was 59 (ranges 35–81). The rate of CR is evaluated separately in subset of HER2+ and HER2- IBC. 100 pts received FAC induction chemotherapy (median number of cycles was 6) and remainder received CMF regimen (median number of cycles was 5), trastuzumab none. Only seven pts (5,6%), all treated with FAC achieved CR. Among them, four had HER-2 3+ (4/25; CR 16%) and three HER2 negative IBC (3/99; CR 3%). Median duration of CR in HER-2+ subset was 15 months (range 7–36+) and in HER-2- 18 months (range 7–101+). Conclusions: Our study shows that incidence of IBC in Serbia is higher than reported in the literature, 8,1% vs 1–4%. Also, it has been shown that very low percentage of IBC patients achieved CR after chemotherapy alone, esspecialy in HER-2- subset of IBC-only 3%, compared to 16% in HER-2+ group, even in the absence of trastuzumab, while the duration of CR in both groups were similar. No significant financial relationships to disclose.
YB-1 expression and effectiveness of different dose-intensification strategies in high-risk breast cancer: Five-year follow-up results of prospective randomized WSG-AM-01 trial
Authors: O. Gluz, R. Kates, M. Schmitt, K. Mengele, H. Royer, S. Mohrmann, E. Ting, R. Diallo-Danebrock, M. Kiechle-Bahat, U. Nitz, N. Harbeck
Journal: Journal of Clinical Oncology (2007)

563 Background: Y-box binding protein (YB-1), known as oncogenic transcription factor, is associated with up-regulation of MDR1, alters p53 function, and induces growth of an aggressive phenotype. In high-risk breast cancer, the prospective randomized WSG-AM-01 trial has reported significantly better event-free (EFS) and overall survival (OS) for tandem high-dose (HD) vs. dose-dense (DD) chemotherapy, especially in basal-like und HER2 subgroups. The present study examines the interaction of a drug resistant phenotype induced by YB-1 within the WSG-AM-01 collective at 5-year follow-up. Methods: 236 tumors (116 HD/120 DD) of 403 randomized patients (60%) were available for construction of tissue microarrays and determination of molecular classification by k-clustering of expression of 34 protein markers. Immunostaining of YB-1 by specific peptide antibody was scored semiquatitatively by intensity. Associations of YB-1 staining with other protein expression factors were studied by Pearson correlations. Univariate survival was estimated by Kaplan-Meier analysis and tested by log rank statistics. Multivariate survival modeling was performed by a generalized Cox model, with linear proportional hazards terms in the first block and time-varying interactions in the second block. Results: At a median follow-up of 61.7 months, the WSG-AM-01 confirms a significant EFS and OS benefit for HD in HRBC. In 60% of tumors, there was strong YB-1 expression. YB-1 was significantly associated with several proliferation and drug resistance markers, such as p53, EGFR, S6 and with basal-like/Her2 subtypes.YB-1 expression was highly predictive for response to HD: both EFS (HR=0.29, p=0.001) and OS (HR=0.16, p=0.0001) were significantly improved by HD compared to DD for YB-1 positive tumors; these favorable time-varying hazard ratios signify decreases in early (≤3 years) relapses and deaths, respectively. Conclusions: Among all investigated markers, only YB-1 expression was significantly associated by time- varying interaction analysis with efficacy of HD. The results suggest YB-1 as a potential stratification criterion for future trials as well as a target for treatment of drug resistant HRBC. No significant financial relationships to disclose.
Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial
Authors: V.Y. Shi, N. Foolad, J.N. Ornelas, L.A. Hassoun, G. Monico, N. Takeda, S. Saric, N. Prakash, L.F. Eichenfield, R.K. Sivamani
Journal: British Journal of Dermatology (2016)
Disturbances in Tryptophan Metabolism After a Single Dose of Aflatoxin Bl and Chronic Intoxication with Carbon Tetrachloride
Authors: F. J. Lemonnier, J. M. Scotto, C. Thuong-Trieu
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Disturbances in Tryptophan Metabolism After a Single Dose of Aflatoxin Bl and Chronic Intoxication with Carbon Tetrachloride Get access F. J. Lemonnier, F. J. Lemonnier Search for other works by this author on: Oxford Academic PubMed Google Scholar J. M. Scotto, J. M. Scotto Search for other works by this author on: Oxford Academic PubMed Google Scholar C. Thuong-Trieu C. Thuong-Trieu 3 2Groupes U9 (Director: Professor Caroli) et U56 (Director: Professor Alagille), L'institut National de la Sante et de la Recherche Medicale, Paris, France. 3Address reprint requests to: Groupe U56, INSERM, Hôpital de Bicêtre, France, 94270 Le Kremlin-Bicêtre. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 3, September 1974, Pages 745–749, https://doi.org/10.1093/jnci/53.3.745 Published: 01 September 1974 Article history Received: 27 December 1973 Revision received: 24 April 1974 Accepted: 07 May 1974 Published: 01 September 1974
Transformation of Rhesus Foreskin Cells by Mason-Pfizer Monkey Virus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Roman J. Pienta, Ph.D., Donald L. Fine, Ph.D., Thomasina Hurt, Cathy K. Smith, John C. Landon, Ph.D., Harish C. Chopra, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1972)

When rhesus foreskin cells were infected with Mason-Pfizer monkey virus and subsequently seeded into semisolid agar medium, numerous colonies grew. Colonies picked and replated produced cells with altered morphology. The cultures contained both multinucleated and giant cells and demonstrated loss of contact inhibition on continued culture. The cells also satisfied other criteria for in vitro transformation, i.e., growth in semisolid agar medium and factor-free medium. The cells released virus as determined by infectivity assays and electron microscopy. Tumor-igenic potential of the transformed cells was indicated by their ability to induce palpable masses at the site of inoculation in newborn rhesus monkeys.
HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.
Authors: S. Pakkala, Z. Chen, D. Rimland, T. K. Owonikoko, C. Gunthel, J. C. Brandes, N. F. Saba, W. J. Curran, F. R. Khuri, S. S. Ramalingam
Journal: Journal of Clinical Oncology (2010)

7632 Background: Lung cancer, the most common non-AIDS defining solid organ malignancy, is associated with poor overall outcomes. Yet, the availability of HAART therapy has resulted in significant improvements in HIV disease outcomes. Methods: All pts diagnosed with lung cancer in the Emory University Healthcare System during the HAART era (1995-2008) were included in this analysis. Individual pt charts were reviewed for clinical data. CD4 count at diagnosis was treated as a continuous variable and also dichotomized into a binary variable with 3 different cutoff points (50, 200, and 500). The Pearson's correlation coefficients were estimated for each pair of covariates studied. The Kaplan-Meier method was used for survival analysis. Results: 80 pts were identified for this analysis of which 73 had NSCLC. Pt baseline characteristics were: median age-52 yrs; male-80%; African American-84%; injection drug use-25%; homosexual/bisexual-33%; adenocarcinoma-41%; squamous-32%, and NSCLC-NOS-27%. All pts were smokers with a mean of 37 pack-yrs. At the time of cancer diagnosis, mean CD4 count and viral load were 304 uL and 82,420 copies/ml, respectively. 74% had a prior AIDS diagnosis and 55% had prior exposure to antiretroviral agents. The latency between diagnosis of HIV and lung cancer was significantly shorter in women (4.1 yrs vs. 7.7 yrs, p = 0.02). Only 67% of the pts received anticancer therapy. Approximately 56% of all treated pts received systemic chemotherapy. The 1- and 3-year survival rates were 31% and 4% overall, 25% and 0% for stage IIIB/IV; and 53% and 8% for all treated pts, respectively. Grade 3/4 toxicities occurred in 56% with chemo-radiation and 31% with chemotherapy alone. The OS since cancer diagnosis was significantly better for pts with CD4 count > 200 (p = 0.0298) and > 500 (p = 0.0076). Conclusions: There is a significant difference in the latency between diagnosis of HIV disease and lung cancer between men and women. Though the outcome for lung cancer pts with HIV remains poor, high CD4 count is associated with an improved lung cancer-related survival. No significant financial relationships to disclose.
포스터발표 : 그랜드볼룸 ; 간세포암에서 과발현되는 14-3-3zeta의 RNAi를 통한 발현억제가 암세포 생장 억제와 항암제 감수성 증가에 미치는 영향 연구 (초)
Authors: 최정은, 허원희, 류광수, 김성우, 홍성우, 김송아, 장정원, 배시현, 윤승규
Journal: Clinical and Molecular Hepatology (2010)
Inactivation Of BANK1 By a Novel IGH-Associated Translocation and 5’ Hypermethylation In B-Cell Lymphomas
Authors: Kui Nie, Taotao Zhang, Jiong Yan, Leonardo Boiocchi, Shuhua Cheng, Susan Mathew, Yifang Liu, Amy Chadburn, Attilio Orazi, Daniel M Knowles, Yen-Chun Liu, Wayne Tam
Journal: Blood (2013)
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Authors: Scott D. Ramsey, Aasthaa Bansal, Catherine R. Fedorenko, David K. Blough, Karen A. Overstreet, Veena Shankaran, Polly Newcomb
Journal: Journal of Clinical Oncology (2016)

Purpose Patients with cancer are more likely to file for bankruptcy than the general population, but the impact of severe financial distress on health outcomes among patients with cancer is not known. Methods We linked Western Washington SEER Cancer Registry records with federal bankruptcy records for the region. By using propensity score matching to account for differences in several demographic and clinical factors between patients who did and did not file for bankruptcy, we then fit Cox proportional hazards models to examine the relationship between bankruptcy filing and survival. Results Between 1995 and 2009, 231,596 persons were diagnosed with cancer. Patients who filed for bankruptcy (n = 4,728) were more likely to be younger, female, and nonwhite, to have local- or regional- (v distant-) stage disease at diagnosis, and have received treatment. After propensity score matching, 3,841 patients remained in each group (bankruptcy v no bankruptcy). In the matched sample, mean age was 53.0 years, 54% were men, mean income was $49,000, and majorities were white (86%), married (60%), and urban (91%) and had local- or regional-stage disease at diagnosis (84%). Both groups received similar initial treatments. The adjusted hazard ratio for mortality among patients with cancer who filed for bankruptcy versus those who did not was 1.79 (95% CI, 1.64 to 1.96). Hazard ratios varied by cancer type: colorectal, prostate, and thyroid cancers had the highest hazard ratios. Excluding patients with distant-stage disease from the models did not have an effect on results. Conclusion Severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a risk factor for mortality. Further research is needed to understand the process by which extreme financial distress influences survival after cancer diagnosis and to find strategies that could mitigate this risk.
Abstract 14992: Outcomes of Off-Label Use of Transcatheter Aortic Valve Replacement (TAVR) in the U.S.: Insights From the STS/ACC TVT Registry
Authors: Ravi S Hira, Salim S Virani, Sreekanth Vemulapalli, Zhuokai Li, Mahboob Alam, Hani Jneid, James McCabe, Mark Reisman, Neal S Kleiman
Journal: Circulation (2015)

Background: TAVR was approved by the US FDA for treatment of severe aortic stenosis (AS) in symptomatic inoperable and high-risk patients. Off-label use of TAVR in the US has not been previously studied. Methods: Patients receiving commercially funded TAVR in the US are included in the Transcatheter Valve Therapy (TVT) Registry. Within this registry, we assessed 23,841 patients from 328 sites receiving TAVR between 11/201-9/2014. We evaluated the frequency and outcomes of off-label TAVR use, defined as TAVR in patients with known bicuspid or unicuspid valve, failing bioprosthetic aortic valve, moderate AS, severe mitral or aortic regurgitation or subaortic stenosis. Data were linked with CMS for 15,394 patients to evaluate 30-day and 1-year outcomes. Results: Off-label TAVR was used in 2682/23841 patients (11.2%); indications noted in the Table 1. Compared to on-label use, off-label use patients were more likely to be younger, male, receive care in urban, teaching hospitals with higher TAVR volume, have higher STS score (median 7.2 vs 6.8, p &lt;0.0001) and less likely to have elective procedures. In CMS-linked data, patients undergoing off-label TAVR had higher 30-day mortality but similar 1 -year mortality compared to on-label TAVR (Table 2). Conclusion: About 1 in 10 patients in the US have received TAVR for an off-label indication. One-year outcomes were similar to on-label indication patients. These results reinforce the urgent need for additional research on the efficacy of TAVR in specific patient cohorts for whom TAVR is being considered in clinical practice.
Breast conservation therapy as a safe and effective alternative to mastectomy for selected T4 patients treated with primary chemotherapy as part of multimodality approach
Authors: M. T. Ionta, A. Scanu, G. L. Masia, A. M. Carta, A. Contu, A. Farris, A. M. Catino, S. Palmeri, L. Minerba, B. Massidda
Journal: Journal of Clinical Oncology (2005)

866 Background: Historically standard locoregional treatment for T4 breast cancer was mastectomy (MRM) and/or radiotherapy. Actually, primary chemotherapy as part of multimodality treatment is considered the standard of care for the management of locally advanced breast cancer including T4 tumors, allowing breast conservation treatment (BCT) in some pts. Most studies however, excludes from this latter approach pts with initially stage T4 assuming unacceptably high locoregional (LRR) and ipsilateral breast recurrences (IBTR). Purpose: To demonstrate feasibility and effectiveness of BCT in selected T4 breast cancer pts after primary chemotherapy as part of multimodality treatment. Methods: From 1996 to 2001, 72 consecutive III B breast cancer pts, median age 51 (29–70); premenopausal 47%; T4abc 55 (77%); T4d 17 (23%); clinical axillary nodes positive 88%, received 4–6 cycles of PEV regimen (Cisplatin 50 mg/m2, Epirubicin 100 mg/ m2, Vinorelbine 25 mg/m2), every 14–21 days, followed by Surgery, RT, Adjuvant CMF and Hormone-Therapy. Results: Overall 38 pts (69%) initially T4abc and 16 pts (94%) initially T4d had MRM; 33% of pts (17 initially T4abc, 1 initially T4d) had BCT. In BCT group, clinical response rate was 95% (CR 28%); at surgery 17% had pCR; 33% had pT1; 39% had negative axillary nodes according to Sataloff’s classification. At median follow-up time of 77 months (39–99) 18 pts (100%) and 17 pts (95%) were alive without evidence of IBTR and LRR respectively; median DFS and OS were 66 (11–99) and 67 (26–99) months respectively; the 5y DFS and OS were 83% and 89% respectively and 5y DFS and OS for the entire group (72pts) were 64% and 72% respectively (BCT vs MRM p=0.004); Conclusions: In appropriately selected pts with initially stage T4, who had sufficient tumor downstaging, after multimodality treatment with initially primary chemotherapy, BCT, as alternative to MRM, is feasible and effective with good local and distant control of disease. No significant financial relationships to disclose.
Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study
Authors: Yasuaki Sagara, Rachel A. Freedman, Ines Vaz-Luis, Melissa Anne Mallory, Stephanie M. Wong, Fatih Aydogan, Stephen DeSantis, William T. Barry, Mehra Golshan
Journal: Journal of Clinical Oncology (2016)

Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option for the management of ductal carcinoma in situ (DCIS). We sought to determine the survival benefit of RT after BCS on the basis of risk factors for local recurrence.A retrospective longitudinal cohort study was performed to identify patients with DCIS diagnosed between 1988 and 2007 and treated with BCS by using SEER data. Patients were divided into the following two groups: BCS+RT (RT group) and BCS alone (non-RT group). We used a patient prognostic scoring model to stratify patients on the basis of risk of local recurrence. We performed a Cox proportional hazards model with propensity score weighting to evaluate breast cancer mortality between the two groups.We identified 32,144 eligible patients with DCIS, 20,329 (63%) in the RT group and 11,815 (37%) in the non-RT group. Overall, 304 breast cancer-specific deaths occurred over a median follow-up of 96 months, with a cumulative incidence of breast cancer mortality at 10 years in the weighted cohorts of 1.8% (RT group) and 2.1% (non-RT group; hazard ratio, 0.73; 95% CI, 0.62 to 0.88). Significant improvements in survival in the RT group compared with the non-RT group were only observed in patients with higher nuclear grade, younger age, and larger tumor size. The magnitude of the survival difference with RT was significantly correlated with prognostic score (P < .001).In this population-based study, the patient prognostic score for DCIS is associated with the magnitude of improvement in survival offered by RT after BCS, suggesting that decisions for RT could be tailored on the basis of patient factors, tumor biology, and the prognostic score.